Characteristic | HIFU (N = 8) | BSC (N = 16) | PC (N = 16) | p value |
---|---|---|---|---|
Age (years), Median (IQR) | 61.5 (58.2–65.3) | 63.2 (59.4–65.5) | 62.5 (58.1–66.3) |  > 0.1 |
Gender |  > 0.1 | |||
 Male | 6 | 8 | 6 |  |
 Female | 2 | 8 | 10 |  |
BMI(kg/m2), Median (IQR) | 20.5 (18.1–22.5) | 19.5 (17.8–21.8) | 20.0 (19.2–23.0) |  > 0.1 |
Comorbidity |  > 0.1 | |||
 No | 2 | 7 | 8 |  |
 Yes | 6 | 9 | 8 |  |
ECOG performance status |  > 0.1 | |||
 0 | 4 | 4 | 6 |  |
 1 | 4 | 10 | 9 |  |
 2 | 0 | 2 | 1 |  |
Child–Pugh class |  > 0.1 | |||
 Grade A | 7 | 13 | 11 |  |
 Grade B | 1 | 3 | 5 |  |
Liver metastases |  > 0.1 | |||
 Synchronous | 2 | 1 | 1 |  |
 Metachronous | 6 | 15 | 15 |  |
First-line treatment of liver metastases | NA | |||
 Chemotherapy | 2 | – | 16 |  |
 RFA | 2 | – | 0 |  |
 HIFU + TACE | 2 | – | 0 |  |
 HIFU | 2 | – | 0 |  |
Chemotherapy before surgery | 0.09 | |||
 No | 6 | 16 | 15 |  |
 Yes | 2 | 0 | 1 |  |
TNM stage of GC |  > 0.1 | |||
 I | 1 | 4 | 2 |  |
 II | 1 | 3 | 4 |  |
 III | 4 | 8 | 9 |  |
 IV | 2 | 1 | 1 |  |
Number of lymph nodes retrieved, Median (IQR) | 19 (12–26) | 18 (12–27) | 20 (13–25) |  > 0.1 |